In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain-Reference-Cited by-同舟云学术

In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain

Published:2000-02 Issue:2 Volume:22 Page:131-141
ISSN:0192-0561
Container-title:International Journal of Immunopharmacology
language:en
Short-container-title:International Journal of Immunopharmacology

Author:

Nakamura Takehiko,Kloetzer William S,Brams Peter,Hariharan Kandasamy,Chamat Soulaima,Cao Xianjun,LaBarre Michael J,Chinn Paul C,Morena Ron A,Shestowsky William S,Li Yan-Ping,Chen Agnes,Reff Mitchell E

Publisher

Elsevier BV

Subject

Pharmacology,Immunology

Reference38 articles.

1. Two species of human Fce receptor II (FCeRII/CD23): tissue-specific and IL-4-specific regulation of gene expression;Yokota;Cell,1988

2. Two forms of the low-affinity Fc receptor for IgE differentially mediate endocytosis and phagocytosis: identification of the critical cytoplasmic domains;Yokota;PNAS,1992

3. Molecular characterization of the low-affinity IgE receptor FceRII/CD23 expressed by human eosinophils;Abdelilah;International Immunology,1998

4. Expression, structure and function of the CD23 antigen;Delespesse;Advances in Immunology,1991

5. Induction of IL-10 synthesis by human keratinocytes through CD23 ligation: a cyclic adenosine 3′, 5′-monophosphate-dependent mechanism;Becherel;J. Immunol.,1997

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

2. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms;Journal of Clinical Investigation;2022-08-01

3. Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis;Frontiers in Immunology;2020-12-17

4. Past, present, and future of anti‐IgE biologics;Allergy;2020-04-21

5. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab;Nature Communications;2020-01-08